In this study we describe the presence of high anity FGF-2 binding sites in the nuclei of U251MG glioma cells (K d =7 pM). Immunoprecipitation of total cell extracts with FGF receptor (FGFR) 1-4 antibodies showed that U251MG glioma cells express only FGFR1. [ 125 I]FGF-2 cross linking to nuclear extracts followed by FGFR1 immunoprecipitation showed that FGFR1 may account for the nuclear FGF-2 binding sites. Western blot analysis demonstrated the presence of 103, 118 kDa and small amounts of 145 kDa FGFR1 isoforms in the nuclei of glioma cells. All isoforms contain both the Cand N-terminal domains. Nuclear FGFR1 retains kinase activity. Immunocytochemistry using confocal microscopy showed speci®c FGFR1 immunoreactivity within the nuclear interior. In continuously proliferating glioma cells, nuclear FGFR1 is constitutively expressed, independent of cell density. In contrast, in nontransformed human astrocytes, nuclear FGFR1 levels¯uc-tuate with the proliferative state of the cell. In quiescent, con¯uent astrocytes nuclear FGFR1 protein was depleted. An accumulation of nuclear FGFR1 was observed following the transition to a subcon¯uent, proliferating state. Transfection of a pcDNA3.1-FGFR1 expression vector into glioma cells that do not express FGFR1 resulted in the nuclear accumulation of FGFR1, increased cell proliferation, and stimulated transition from the G 0 /G 1 to the S-phase of the cell cycle. The increased proliferative rate was resistant to inhibition by the cell-impermeable FGF binding antagonist, myoinositol hexakis [dihydrogen phosphate]. Our results suggest that the constitutive nuclear presence of FGFR1 contributes to the increased proliferation of glioma cells while the transient nuclear accumulation of FGFR1 in normal astrocytes may play a role in the transition to a reactive state.
Introduction
Proliferation and growth of glial cells underlie both the development and regeneration or remodeling of the mature nervous system (McConnell, 1988; Eng et al., 1992; McMillian et al., 1994; Anderson et al., 1994) . When uncontrolled, these processes may lead to neoplastic transformation and glioma cancers.
Recently we have shown (Moett et al., 1996; Joy et al., 1997) that expression of the mitogenic ®broblast growth factor-2 (FGF-2; bFGF) is increased in reactive astrocytes within epileptic foci of the mature human brain. FGF-2 is a member of a heparin-binding family of growth factors, which is currently comprised of nine structurally related members (Wilkie et al., 1995) . FGF-2 is thought to act by binding to speci®c, high anity cell surface receptors (Mason, 1994) . Activation of these receptors initiates a cascade of signals which propagate toward the nucleus, ultimately leading to the phosphorylation of nuclear proteins and long-lasting changes in cellular metabolism. However, not all the biological eects of FGFs are produced in this manner. In recent years, a number of laboratories have reported the association of FGFs with the cell nucleus, suggesting that at least some of their biological effects are produced through a direct interaction with nuclear eectors (Mason, 1994; Jans, 1994) . Furthermore, stimulation of cell proliferation by intracellular FGFs was observed in several studies (Imamura et al., 1990; Wiedlocha et al., 1994; Bikfalvi et al., 1995; Joy et al., 1997) . The oscillations in the level of endogenous FGF-2 in the nucleus, but not in the cytoplasm, which accompany changes in astrocytic proliferation further suggest that the mitogenic actions of FGF-2 can be produced directly in the nucleus (Moett et al., 1996; Joy et al., 1997) . To explain how nuclear FGFs exert their biological eects, we postulated the presence of nuclear FGF receptors (Stachowiak et al., 1994 (Stachowiak et al., , 1996a .
FGFs are known to interact with two classes of receptors; high anity tyrosine kinase receptors which bind FGFs with picomolar anity and are thought to mediate the cellular responses to FGFs, and low anity receptors which bind FGFs with nanomolar anity and are characterized by the presence of heparan sulfate (Johnson and Williams, 1993; Wilkie et al., 1995) . Currently, four genes are known to encode the high anity FGF receptors (FGFR) (Ruta et al., 1989; Dionne et al., 1990; Keegan et al., 1991; Partanen et al., 1991; Hou et al., 1991) . Each FGFR gene encodes an extracellular domain (N-terminal domain) comprised of three or two immunoglobulin (Ig)-like domains (depending on the splice variant), containing the growth factor binding site, a transmembrane domain, an intracellular tyrosine kinase domain, and a C-terminal domain (Wilkie et al., 1995) . Prodovsky et al. (1994) showed that cell surface FGFR1 redistributes to a cytoplasmic-perinuclear location after stimulation of cells by exogenous FGF-1. Until recently, it was unknown whether FGFRs could be found within the nucleus and thereby act as eectors for intranuclear FGF-2. However, fractiona-tion of human astrocytes or bovine adrenal medullary cells revealed the presence of FGFR1 in isolated nuclei, associated with both the nucleoplasm and nuclear matrix (Stachowiak et al., 1996a,b) . Immunoconfocal microscopy con®rmed the intranuclear presence of FGFR1 and showed colocalization with FGF-2. Nuclear FGFR1 binds FGF-2 and retains tyrosine kinase activity. Thus the presence of functional FGFR in the nucleus suggests that the receptors may mediate the eects of nuclear FGF-2. In the present study we demonstrate: (1) the nuclear localization of functional FGFR1 in human glioma cells, and (2) provide evidence for the mitogenic role of nuclear receptors in glial cell proliferation. (Table 1) . Low and high anity binding sites were also observed with the cytoplasmic fraction, while only high anity binding sites were found in the nuclear fraction. In all cases, speci®c binding was eliminated by a 100-fold molar excess of unlabeled FGF-2.
Results

Scatchard
FGFR1 is the predominant subtype of FGFR expressed in U251MG glioma cells
In human astrocytes, FGFR1 was identi®ed as the predominant type of FGF-2 receptor (Stachowiak et al., 1996a) . To determine the types of high anity FGFR expressed in U251MG glioma cells, FGFRs were immunoprecipitated from total cell extracts with antibodies speci®c to the C-terminal domains of FGFR1-4 (Santa Cruz Biotechnology). The immunoprecipitates were subjected to Western analysis with a monoclonal FGFR antibody (McAb6) that recognizes a common sequence in the N-terminal, extracellular domains of FGFR1-4 (Hanneken et al., 1995) . The results show that FGFR1 is the predominant FGFR in U251MG glioma cells (Figure 1 ). FGFR1 isoforms of 103, 118 and 145 kDa were observed, consistent with the earlier reported sizes for FGFR1 (Xu et al., 1992) . Since all these isoforms contain both the C-terminal and N-terminal domains they are likely to represent the full length receptors.
Subcellular distribution of FGFR1
To determine the subcellular localization of FGFR1 in glioma cells, we isolated nuclear and cytoplasmic fractions as described previously (Boyle et al., 1985; Stachowiak et al., 1994; 1996a,b) . Nuclei isolated by this method contain nearly 90% of the total TCAprecipitable cellular DNA. Analysis of the isolated nuclei by phase-constant microscopy showed no contamination with cytoplasmic membranes and organelles. The purity of the isolated nuclei was con®rmed using biochemical assays of marker enzymes. The nuclear fraction contained 5+2% of the total cellular activity of acid phosphatase (lysosomal marker) and 8+3% of the 5'-nucleotidase (cell membrane marker). Western blot analysis of nuclear extracts of U251MG cells using the monoclonal FGFR antibody (McAb6) detected proteins of 103 and 118 kDa. An additional lower abundance 145 kDa protein was detected after longer exposure (not shown). The speci®c content of FGFR1 in the nuclear fraction was approximately 2 ± 3-fold higher than in the total cell lysates (Figure 2a ). Only trace amounts of FGFR1 were detected in the cytoplasmic fraction. The apparent molecular weights of FGFR1 isoforms in the nuclei of U251MG cells are identical to those found in the nuclei of human astrocytes (Stachowiak et al., 1996a) .
We used immunohistochemistry in combination with confocal microscopy to provide a topological evaluation of the distribution of FGFR1 in glioma cells and astrocytes. Cells were stained with the C-term FGFR1 Ab. The distribution of FGFR1 immuno¯uorescence was analysed using 2-dimensional projections of a series of confocal images (Figure 2b ). Astrocytes (Figure 2b ,II) and U251MG glioma cells (Figure 2b, III) Figure  2b ,I) or replacing it with preimmune serum abolished nuclear staining (not shown). Nuclear FGFR1 immuno¯uorescence also was eliminated after the Cterm FGFR1 Ab was preincubated with an excess of its cognate peptide (Stachowiak et al., 1996a) . Using the same staining protocol, we detected non-nuclear glial acidic ®brillary protein (GFAP) exclusively in the cytoplasm (Joy et al., 1997) .
The observed pattern of immuno¯uorescence could be due to perinuclear, nuclear membrane or intranuclear staining. To distinguish between these localizations, we analysed a series of consecutive 2 mm confocal laser sections through cells stained with the C-term FGFR1 antibodies (Figure 2b,IV) . The pattern seen in these sections shows that FGFR1 immunouorescence is present within the nuclear interior. Therefore, based on the results of biochemical 
The nuclear content of FGFR1 in astrocytes is regulated by cell density
In con¯uent, quiescent astrocytes, transcription of the FGF-2 gene is down-regulated and nuclear FGF-2 is depleted (Moett et al., 1996; Joy et al., 1997) . After transition to a subcon¯uent state, astrocytes proliferate, express the FGF-2 gene, and accumulate nuclear FGF-2. We examined whether the nuclear content of FGFR1 is also co-regulated with cell density in astrocytes. The reduction of nuclear FGFR1 content concomitant with an increase in cell density was initially detected using immunostaining, as visualized with peroxidase and diaminobenzidine. One week after plating, subcon¯uent astrocytes exhibited intense nuclear FGFR1 immunoreactivity (Figure 4a,I ). Three weeks after plating, when a con¯uent monolayer covered the dish, no nuclear FGFR1 immunoreactivity could be detected in the astrocytes (Figure 4a ,II). As with FGF-2, the depletion of nuclear FGFR1 was reversible. In the vacant surfaces left by detached, con¯uent astrocytes, we observed nuclear FGFR1 immunoreactivity in astrocytes invading those areas (not shown). Similar results were observed with primary astrocytic cultures obtained from the frontal lobes of two dierent subjects (not shown).
In addition to immunocytochemistry, the cell density-dependent regulation of nuclear FGFR1 content in astrocytes was con®rmed by Western blot analysis. Figure 4b shows the time dependent accumulation of FGFR1 in astrocytic nuclei following a reduction in cell density. We used the C-term FGFR1 Ab for these experiments, which recognizes predominantly the 103 kDa hypoglycosylated isoform of FGFR1 (Hanneken et al., 1995, Maher unpublished observations) . The level of the 103 kDa FGFR1 isoform in nuclei from con¯uent astrocytes was low and remained reduced for at least 6 h after cells were . Cells were incubated with C-term FGFR1 Ab. Immune complexes were stained by incubating with biotinylated secondary antibody, avidin-biotin peroxidase, and diaminobenzidine-peroxide solution. I ± subconuent astrocytes (1 week in culture) show nuclear FGFR1 immunoreactivity; II ± con¯uent astrocytes (3 weeks) ± no nuclear FGFR1 staining is detected. (b) Time-dependent accumulation of FGFR1 after reduction of cell density. Astrocytes (SS strain) were maintained in con¯uent state for 48 h. Some cultures were replated at lower density (approx. 30% of con¯uence). Nuclear (N) and cytoplasmic (C) extracts were analysed for FGFR1 using C-term FGFR1 Ab. (c) Timedependent increase in FGFR1-associated kinase activity after reduction of cell density. Cytoplasmic (C) and nuclear (N) extracts from cultures maintained in subcon¯uent state for 2 and 18 h were immunoprecipitated with the C-terminal FGFR1 antibody. Immunoprecipitates were incubated with [g- replated at a subcon¯uent density. Between 6 and 18 h after the cell density was reduced, a marked increase in nuclear FGFR1 content occurred followed by a small decline after an additional 6 h. Next we examined whether the FGFR1 which accumulates in the nuclei of subcon¯uent astrocytes has tyrosine kinase activity. FGFR1-associated kinase activity was examined 2 and 18 h after replating the astrocytes; before and while the increased nuclear accumulation of FGFR1 protein is detectable. Immunoprecipitation of nuclear FGFR1 followed by incubation with [g 32 P]ATP showed a phosphorylated band at 103 kDa (Figure 4c ), similar in size to the FGFR1 bands detected by immunoblotting ( Figure 4b ) and a broader band between 118 and 145 kDa, consistent with the migration of the higher molecular weight, glycosylated isoforms of FGFR1. In addition, unidenti®ed, coprecipitating products, which migrated slower than the IgG heavy chain, became phosphorylated. They could represent potential targets for nuclear FGFR1. Phosphorylated FGFR1 bands were not detected in the nuclear extracts incubated with control IgG (not shown). Thus, nuclear accumulation of FGFR1 protein is accompanied by an increase in receptor kinase activity.
Deregulation of nuclear FGFR1 distribution in U251MG glioma cells
In contrast to astrocytes, the U251MG glioma cells exhibited similar amounts of nuclear FGFR1 immunoreactivity in both the con¯uent and subcon¯uent state (Figure 5a, I and II, respectively). The impaired cell density-dependent depletion of nuclear FGFR1 in glioma cells was also con®rmed by Western blot analysis. The C-term FGFR1Ab detected a high content of nuclear 103 kDa FGFR1 in dense cultures of U251MG cells (Figure 5b ). While the C-term FGFR1 Ab recognizes predominantly the 103 kDa hypoglycosylated isoform of FGFR1, McAb6 reacts with both the 103 kDa FGFR1 isoform as well as the hyperglycosylated 118 and 145 kDa isoforms. Figure  5c compares the nuclear content of FGFR1 in subcon¯uent and con¯uent glioma cells using McAb6. In an eort to determine the function of nuclear FGFR1 we have identi®ed a glioma cell line, SF-763, that does not express FGFR1. Immunoprecipitation with antibodies speci®c to the C-terminal of FGFR1 ± 4 showed that FGFR2 and FGFR3 are the predominant types of FGFR in SF-763 glioma cells, while FGFR1 and FGFR4 are not detected (Figure 6a ). We examined whether ecoptic expression of FGFR1 in SF-763 glioma cells can result in nuclear accumulation of FGFR1 and aect cell proliferation. SF-763 cells were transfected with the pcDNA3.1-FGFR1 plasmid containing full length FGFR1 cDNA or with the control plasmid pcDNA3.1, lacking the FGFR1 cDNA insert. A population of G418 resistant, stably transfected cells was obtained. The cells were lysed with 0.6% NP-40 in hypotonic buer, and nuclei were separated from the extranuclear material (cytoplasm and cell membranes) by centrifugation. The nuclear fraction obtained by this method showed a similar lack of signi®cant contamination with plasma membrane or lysosomal proteins as the nuclei obtained by the isotonic lysis method (Figure 2a ). Fractions were analysed by Western blot with FGFR1-speci®c antibody (Santa Cruz Biotechnology; Figure 6b ). A major, 145 kDa band was detected in the nuclei of SF-763-pcDNA3.1-FGFR1 cells while only trace amounts of FGFR1 were found in the extranuclear fraction containing both the cytoplasm and cell membranes. No FGFR1 was detected in SF-763-pcDNA3.1 cells (Figure 6b ). Consistent with these results, we observed the presence of FGFR1-associated kinase activity in SF-763 cell lines expressing recombinant FGFR1 but not in pcDNA3.1 transfected cells (Figure 6c) .
The subcellular localization of FGFR1 in transfected SF-763 cells was also examined by immunocytochemistry. The SF-763-pcDNA3.1-FGFR1 cells exhibited FGFR1-immunoreactivity, predominantly within the nucleus (Figure 7a ). Staining was not detected when the primary antibody was omitted (not shown). In contrast, the SF-763-pcDNA3.1 cells did not show speci®c FGFR1 staining with the C-term-FGFR1Ab (Figure 7c) .
The SF-763-pcDNA3.1-FGFR1 cells also exhibited an increased proliferation rate as compared to the SF-763-pcDNA3.1 cells (Figure 8a ). This accelerated proliferation is likely to represent an increased mitotic activity of individual cells. Flow-cytometry showed that in cell lines transfected with pcDNA3.1-FGFR1 the number of cells residing in S phase increased 30% with a concomitant decrease in the proportion of cells in G 0 / G 1 phases relative to cells transfected with the pcDNA3.1 plasmid (not shown). To determine if the mitogenic eect of transfected FGFR1 is mediated intracellularly we used myo-Inositol hexakis [dihydrogen phosphate] (IP6), a cell-impermeable antagonist which prevents the interaction of FGF-2 with cell surface FGFR but does not inhibit the eects of intracellular FGF-2 (Sherman et al., 1993; Morrison et al., 1994a) . IP6 preferentially inhibited the proliferation of the SF-763-pcDNA3.1 cells (IC 50 =251 mM) as compared with the SF-763-pcDNA3.1-FGFR1 cells (IC 50 =3013 mM) cells (Figure 8b ). The resistance of the SF-763-pcDNA3.1-FGFR1 cells to IP6 suggests that their increased proliferative rate is independent of cell surface FGFR and could be mediated by the nuclear FGFR1.
Discussion
Recently, we showed that the expression of nuclear FGF-2 is induced in reactive astrocytes within the epileptic foci of the mature human brain and in glioma tumors (Joy et al., 1997) . In order to determine if high anity FGFR could mediate the eects of nuclear FGF-2 in astrocytes and glioma cells we examined the intracellular distribution of FGFR within these two cell types.
The studies reported here demonstrate an intranuclear localization for FGFR1 in human glioma cells and con®rm our earlier ®nding that the nuclei of human astrocytes contain functional FGFR1 (Stachowiak et al., 1996) . Furthermore, nuclear FGFR1 is a full length protein since its size is similar to the largest FGFR1 predicted by the cDNA (approximately 96 kDa; Dionne et al., 1990; Hou et al., 1991) and is recognized by antibodies to both the extracellular domain (McAb6) and the C terminal domain of the receptor. Consistent with the presence of full length receptor in the nucleus are the observations that nuclear FGFR1 binds FGF-2 and retains tyrosine kinase activity. In a separate study we found that treatment of nuclear extracts with Nglycanase converts the 103, 118 and 145 kDa isoforms into a single approximately 100 kDa protein (our unpublished observations). Thus, the 103, 118 and 145 kDa bands appear to represent dierent degrees of glycosylation of FGFR1. The results of our crosslinking experiments suggest that the 118 and 145 kDa bind eciently FGF-2.
Recently, Johnston et al. (1995) reported that nucleicontaining subcellular fractions isolated from breast cancer cell lines contain FGFR3 and suggested that the association of FGFR3 with the nuclear fractions may be caused by a deletion of its transmembrane domain. In our study, we show that transfection of cells with the pcDNA3.1-FGFR1 plasmid containing the full length FGFR1 cDNA, into SF-763 cells results in an accumulation of FGFR1 in the nuclei. This suggests that the full length receptor can translocate to the nucleus. Cell surface labeling of U251MG cells with an impermeable analog of biotin followed by extended incubation at 378C did not result in any biotin-labeled FGFR1 in the nuclei indicating that FGFR1 can move to the nucleus without prior insertion into plasma membrane (P Maher and MK Stachowiak, in preparation). The import of many proteins into the nucleus is mediated by nuclear localization signals (NLSs). Most characterized NLSs consist of a stretch of 3 ± 5 basic residues, often¯anked by proline or glycine (Chelsky et al., 1989) . Basic amino acids present in FGFR1 do not form typical NLS-like clusters. It is possible that the movement of FGFR1 to the nucleus is mediated by a chaperon protein.
Whether FGFR1 is translocated to the nucleus complexed with cytoplasmic FGF-2 or other proteins is under investigation. A distinct, NLS-independent nuclear transport system that imports glycosylated proteins from the cytoplasm into the nucleus in a sugar-dependent manner has been identi®ed (Duverger et al., 1995) . Unlike the NLS-mediated transport that often direct proteins to the nucleoli, the sugar-mediated transport results in general nuclear localization (as observed for FGFR1).
The intranuclear content of FGFR1 oscillates in association with cell proliferation. Quiescent astrocytes maintained in high-density cultures had little or no nuclear FGFR1 (Figure 4 ). After the cell density was reduced, cell hypertrophy and transient proliferation were observed accompanied by an induction of nuclear FGFR1. In contrast to the transient burst of controlled growth experienced by reactive astrocytes in gliotic tissue, neoplastic glioma cells proliferate continuously, unresponsive to external cues such as cell contact inhibition. This constitutive proliferation was also observed in vitro. After con¯uent monolayers were formed, cultured U251MG cells continued to produce additional layers. Nuclear FGFR1 decreased only slightly as the glioma cells reached con¯uence. In our other reports, we show that the nuclear content of FGF-2 is regulated in a manner similar to FGFR1 in astrocytes and glioma cells (Moett et al., 1996; Joy et al., 1997) . Also FGF-2 and FGFR1 are both associated with the nuclear matrix (Stachowiak et al., 1996a; Joy et al., 1997) and nuclear FGFR1 is capable of binding FGF-2 (Stachowiak et al., 1996a; present study) . Thus, nuclear FGFR1 could serve as an eector for nuclear FGF-2.
To address the role of nuclear FGFR1 in cell proliferation, we transfected SF-763 glioma cells with a pcDNA3.1-FGFR1 plasmid and examined proliferation rate in the absence or presence of IP6, a cellimpermeable FGF binding antagonist (Sherman et al., 1993; Morrison et al., 1994a) . Unlike U251MG, the SF-763 glioma cells express FGFR2 but not FGFR1, consistent with earlier reported dierences in FGFR expression in human glioma tumors (Morrison et al., 1994b) . FGFR1 was found intracellularly in transfected cells where it was localized almost exclusively to the nucleus. The expression of nuclear FGFR1 was accompanied by an increase in spontaneous cell proliferation in the absence of exogenously added FGF-2. The increase in proliferation of the SF-763-pcDNA3.1-FGFR1 cells was associated with increased mitotic activity of the individual cells. Our results indicate that nuclear FGFR1 stimulates the transition from the G 0 /G 1 to the S phase of the cell cycle. IP6 inhibited the proliferation of the SF-763-pcDNA3.1 cells suggesting that these cells proliferate in response to an extracellular growth factor which acts through cell surface FGFR. Since we could not detect FGF-2 in the medium conditioned by SF-763 cells (MK Stachowiak and R Florkiewicz, unpublished observations) , other members of the FGF family may be responsible for this activity and may act through FGFR2 and/or FGFR3 (Figure 6a) . In contrast to the SF-763-pcDNA3.1 cells, the spontaneous proliferation of the SF763-pcDNA3.1-FGFR1 cells was resistant to IP6 (Figure 8b ) providing strong evidence that the increase in the proliferation of the SF-763-pcDNA3.1-FGFR1 cells occurs independently of cell surface FGFR and may depend on nuclear FGFR1.
Our study suggests that the cellular eects of FGFs can be mediated by an intracellular (intracrine) pathway that operates through nuclear FGFR1. Thus, cells could regulate their responsiveness to FGFs by controlling both the expression and the subcellular localization of FGFR. The presence of functional FGFR1 within the nucleus may explain how intracellular FGFs exert the mitogenic eects observed in this (Joy et al., 1997) and in other laboratories (Imamura et al., 1990; Wiedlocha et al., 1994; Bikfalvi et al., 1995) .
We propose that the regulation of both FGFR1 (present study) and FGF-2 (Moett et al. 1996; Joy et al., 1997) content in the nucleus could serve as a novel mechanism controlling proliferation in glial cells.
Thus, transient nuclear accumulation of FGF-2 and FGFR1 may mediate the reversible mitotic activation of quiescent astrocytes. In glioma cells, the constitutive nuclear presence of FGF-2 and FGFR1 may promote proliferation that is insensitive to cell contact inhibition. Further analysis of the nuclear translocation and function of FGF-2/FGFR1 may reveal the mechanisms controlling normal and neoplastic growth of glial cells.
Materials and methods
Materials
Culture media were from Grand Island Biologicals (Grand Island, NY). The remaining reagents were from Boehringer Mannheim (Indianapolis, IN) , Sigma Chemical Co. (St. Louis, Mo), Bio-Rad (Richmond, CA), Stratagene (La Jolla, CA), Du Pont NEN (Boston, MA), Pharmacia (Alameda, CA); Santa Cruz Biotechnology (Santa Cruz, CA), Genzyme (Cambridge, MA) and Pierce (Rockford, IL).
Astrocytic and glioma cell cultures and cell fractionation
Two normal astrocyte cultures (QG and SC) obtained from the dissociation of brain tissue taken from dierent trauma patients are described in (Moett et al., 1996; Stachowiak et al., 1996a) . Cells were prepared and maintained in Waymouth 87/3 medium (MAB) supplemented with 20% fetal bovine serum. Established glioma cell lines U251MG (Binger et al., 1981) and SF-763 (Berens et al., 1990) were used. Cell fractionation was performed by the isotonic method of Boyle et al. (1985) or by the hypotonic/NP-40 lysis method of Schreiber et al. (1989) as described in Stachowiak et al. (1994 Stachowiak et al. ( , 1996a Joy et al., 1997) . In the isotonic protocol cells were lysed in nuclear buer containing 0.1% digitonin, 5 mM sodium phosphate pH 7.4, 50 mM NaCl, 150 mM sucrose, 5 mM KCl, 2 mM dithiothreitol, 1 mM MgCl 2 , 0.5 mM CaCl 2 , 0.1 mM PMSF, 10 mM leupeptin, 1 mg/ml aprotinin, 25 mg/ml soybean trypsin inhibitor, and 5 mg/ml pepstatin A. Nuclei were collected by centrifuging at 500 g for 10 min at 48C. The postnuclear supernatant was further centrifuged at 40 000 g for 30 min at 48C and the supernatants were reserved for analysis of cytoplasmic FGFR. The crude nuclear pellet was further puri®ed by centrifugation through a cushion of TN buer (2.5 mM Tris HCl, pH 7.4, 10 mM NaCl) containing 30% sucrose at 1000 g for 10 min at 48C. In the hypotonic protocol, cells were washed in Tris-buered saline, swollen in homogenization buer containing 10 mM HEPES, pH 7.9, 10 mM KCl, 0.1 mM EDTA, 0.1 mM EGTA, 1 mM DTT, 0.5 mM PMSF, and vortexed in homogenization buer containing 0.6% NP-40. Nuclei were pelleted by centrifugation for 30 s in a microfuge, and washed in homogenization buer containing NP-40. The nuclear pellet and the supernatant containing both cytoplasm and plasma membranes were used for further analyses. The isolated nuclei were washed three times in the isotonic nuclear buer. The purity of isolated fractions was evaluated by measuring the activity of plasma membrane 5'-nucleotidase and lysosomal acid phosphatase using Sigma Chem. Co. assay kits as suggested by the manufacturer.
Binding of [
125 I]human recombinant FGF-2 to cell surface and to the nuclear and cytoplasmic fractions of U251MG glioma cells Nuclei and cytoplasmic fractions were isolated as described above. The binding of [
125 I]FGF-2 was examined using the method of Moscatelli et al. (1987) . Cells were plated overnight at 1610 6 /well in 12-well plates in serum-free MEM containing 0.15% gelatin. Subsequently cells were washed twice with ice-cold PBS and were incubated for 4 h at 48C in 100 ml MEM containing 25 mM HEPES, 0.15% gelatin and increasing concentrations (0 ± 50 nM) of [ 125 I]FGF-2 with or without 100-fold molar excess of unlabeled FGF-2. Cells were washed three times with PBS and the low binding anity fraction was extracted with 1 ml of 2 M NaCl in 20 mM HEPES, pH 7.5. The high anity binding fraction was obtained by solubilizing the cells in 250 ml of 0.5% Triton-X100 in 0.1 M sodium phosphate, pH 8.1. Each fraction was counted for [ 125 I]FGF-2 using a Tracor Gamma counter. Nuclear and cytoplasmic fractions were collected from 10 6 cells and diluted with binding buer (25 mM HEPES, pH 7.5, 0.15% gelatin) and the indicated concentrations of [
125 I]FGF-2 (speci®c activity 70 mCi/mg). The binding was carried out in suspension at room temperature for 2 h in gently rotating tubes in the presence or absence of 100-fold excess of unlabeled FGF-2. The reaction mixtures were transferred to Amicon-50 Microconcentrators and centrifuged 10 min, 6000 g, at room temperature. The ligand-bound, ®lter-retained fraction of [
125 I]FGF-2 was counted and analysed utilizing the Mac Ligand program according to Munson and Rodbard (1980) . Presence of dierent anity binding sites on the cell surface or in the cytoplasmic or nuclear fraction was evaluated by computing the`r' coecient (a statistical value which describes the accuracy between inter-sample variance).
Cross linking of [
125 I]FGF-2 to receptors and immunoprecipitation of cross-linked FGFR [ 125 I]FGF-2 was prepared as described using lactoperoxidase (Schubert et al., 1987) . The free iodine was separated from the iodinated growth factor by passage over a heparan-Sepharose column. Speci®c activity was 4 ± 6610 5 c.p.m./ng. For cross-linking, cells were incubated with 10 6 c.p.m./ml of [ 125 I]FGF-2 in 150 mM NaCl, 20 mM HEPES, pH 7.5 for 2 h with rocking and were rinsed twice with PBS. Cells, cytoplasmic fractions or nuclear extracts were incubated with 0.15 mM disuccinimidyl suberate (DSS; Sigma Chemical Co.) in PBS for 15 min at room temperature with rotation. The cross-linking was stopped by the addition of 200 mM ethanolamine. The samples were rinsed twice with PBS and then solubilized in 500 ml of Triton X-100 buer (1% Triton X-100, 50 mM HEPES, pH 7.5, 50 mM NaCl, 5 mM EDTA, 1 mM Na 3 VO 4 ). FGFRs were immunoprecipitated at 48C overnight with antibodies against the C-terminal domains of the dierent types of FGFR (FGFR1 ± 4 ± Santa Cruz Biotechnology) as described below. The immunoprecipitates were collected on protein A-sepharose, washed twice with 0.1% Triton X-100 buer in 20 mM HEPES, pH 7.5, 150 mM NaCl, once with phosphate-buered saline (PBS) and solubilized in 46SDS-sample buer. The samples were separated on SDS-7.5% polyacrylamide gel and the gel was dried and autoradiographed.
Western analysis of FGFR in subcellular fractions
Western analysis of FGFR was performed as described in Stachowiak et al. (1996) . Brie¯y, protein concentrations were determined using the Bio-Rad protein assay (Bio-Rad, Richmond, CA). Equal amounts (50 mg) of proteins from total cell lysate, cytoplasmic or nuclear fractions were solubilized in 46SDS-sample buer and separated on SDS-7.5% polyacrylamide gel and transferred to nitrocellulose membrane. The transfers were stained with amido black to con®rm the presence of equal amounts of protein in each lane. Blots were probed using a polyclonal, anity-puri®ed rabbit antibody to the carboxyl terminus of FGFR1 (Cterm-FGFR1Ab; Hanneken et al., 1995) . The C-term FGFR1 Ab does not cross-react with FGFR2, FGFR3 or FGFR4 receptors (Hanneken et al., 1995) . The second antibody used was a monoclonal antibody (McAb6) against the extracellular domain of FGFR1 produced in baculovirus which was characterized as described in (Hanneken et al., 1995) . Nitrocellulose membranes were blocked with 0.1% Tween 20 (C-term FGFR1 Ab) or 5% nonfat milk (McAb6) in Tris-buered saline overnight prior to incubation with antibodies. Membranes were incubated with C-term FGFR1 Ab (2 mg/ml) for 4 h, washed and then treated with 125 I-labeled protein A (0.2 mCi/ml). For McAb6, the transfers were incubated overnight with the antibody (3 mg/ml), washed and then incubated with 1 mg/ ml of rabbit anti-mouse IgG for 2 h prior to the addition of [ 125 I]protein A as described above. The transfers were autoradiographed overnight at 7708C. The apparent molecular sizes of FGFR forms were determined by comparison to concurrently run protein molecular weight standards. FGFR1 protein levels in the fractions were estimated by densitometric scanning of autoradiograms using a Beckman DU70 spectrophotometer.
Immunoprecipitation of FGFR and in vitro phosphorylation assays
Nuclear proteins were solubilized by sonication of the isolated nuclei in Triton X-100 buer to give a ®nal protein concentration of 1 mg/ml. FGFR were immunoprecipitated from the total cell lysates or from the cytoplasmic or nuclear extracts at 48C overnight with the commercial anti-FGFR1 antibody (Santa Cruz Biotechnology; 0.5 mg/500 ml nuclear extract). The immunoprecipitates were collected on protein A-Sepharose, washed 36 with 0.1% Triton X-100 in 20 mM HEPES, pH 7.5, 1 mM Na 3 VO 4 , 150 mM NaCl and resuspended in 50 ml in vitro phosphorylation buer (150 mM NaCl, 20 mM HEPES, pH 7.5, 0.1% Triton X-100) containing 10 mM MgCl 2 , 50 mM MnCl 2 , 1 mM Na 3 VO 4 , 50 nM ATP and 10 mCi[g 32 P]ATP (speci®c activity 6000 Ci/mmol). The reaction was carried out for 20 min at room temperature with continuous rotation and then terminated by the addition of an equal volume of 46SDS-sample buer. The samples were separated on SDS-7.5% polyacrylamide gels and the gels were ®xed overnight in 25% methanol, 10% acetic acid, dried and autoradiographed for 12 ± 18 h.
Immunocytochemical staining
Cultured cells were ®xed, permeabilized with 1.0% Triton X-100, and stained immunocytochemically as in (Stachowiak et al., 1994 (Stachowiak et al., , 1996 with the same FGFR1 antibodies (C-term FGFR1Ab or McAb6; Hanneken et al., 1995) that were used in Western blot assays. Immune complexes were detected with biotinylated secondary antibody, followed by avidin-linked peroxidase and diaminobenzidine-hydrogen peroxide solution (Stachowiak et al., 1994) . Endogenous peroxidase activity was exhausted by treating cells with 0.1% H 2 O 2 . Immuno¯uorescent staining of FGFR1 was performed using CY 3 -conjugated secondary antibodies (Jackson Immuno Research Labs., West Grove, PA) as described in (Stachowiak et al., 1996a) . Digitized images of 1 mm confocal optical sections were acquired using a Biorad MRC 600 confocal microscope with a YHS 568 nm ®lter and 15 mW Crypton/Argon laser. The images were recorded directly onto 35 mm ®lm.
The speci®city of FGFR1 immunostaining was indicated by several observations: (1) staining was not observed when the primary antibody was omitted or replaced with preimmune serum; (2) similar staining was observed using two dierent antibodies (C-term FGFR1 Ab and McAb6) and dierent staining techniques; (3) the same staining technique detected FGFR1 in the nuclei (Figure 7 ) and the cytoplasmic glial acidic ®brillary protein in the cytoplasm (Joy et al., 1997) ; (4) neutralization of the C-term FGFR1 Ab by an excess of the C-terminal FGFR1 peptide reduced FGFR1 staining (Stachowiak et al., 1996a) ; (5) the presence, absence and dierences in the levels of nuclear FGFR1 immunoreactivity were con®rmed by Western blot analysis of FGFR1 in subcellular fractions; and (6) transfection of FGFR1 expressing plasmid into glioma cells that do not express FGFR1 led to an induction of nuclear FGFR1 immunoreactivity.
Proliferation of glioma cells expressing recombinant FGFR1
pcDNA3.1-FGFR1 vector was constructed by cloning the 2494 bp XbaI cDNA fragment containing the entire coding sequence of the three-loop form of human FGFR1 (Hou et al., 1991) into the XbaI site 3' to the cytomegalovirus (CMV) immediate early promoter of the pcDNA3.1 plasmid (Invitrogen). pcDNA3.1 contains a G418 resistance gene for selection of stable transfectants. The pcDNA3.1-FGFR1 directs the expression of a complete FGFR1. SF-763 Glioma cells (3610 6 cells/ml) were transfected with 100 mg of pcDNA3.1-FGFR1 or control pcDNA3.1 plasmids using electroporation. Two days after transfection the cells were maintained with 400 mg/ml of G418 (Stratagene) to select transfectants. G418-resistant cells were pooled to establish populations of stabletransfected cells. The proliferation of transfected glioma cells was examined according to Brasaemle and Attie (1988) . Brie¯y, cells were plated in 96-well plates at 2610 3 cells/well in medium containing 5% serum. To determine cell densities at the indicated times, the cells were ®xed and stained with crystal violet (0.01%) and solubilized with 10% SDS. The changes in cell number were quanti®ed by reading the absorbance at 540 nm on an automated ELISA plate reader. The inhibition of cell proliferation by IP6 was analysed by interactive nonlinear least square analysis to give the accurate concentration of IP6 needed to inhibit cell proliferation by 50% (ID50) (Draper and Smith, 1966) .
Cell cycle analysis by¯ow cytometry was carried out according to Latham et al. (1996) as described in Joy et al. (1997) . DNA histograms were generated using EPICS Pro®lē ow cytometer (Coulter Co. Hialeh, Fl) and were analysed using Multicycle cell cycle analysis program (Phoenix Flow Systems, San Diego, CA). 
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